These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 24604503)
1. The role of the apelinergic and vasopressinergic systems in the regulation of the cardiovascular system and the pathogenesis of cardiovascular disease. Czarzasta K; Cudnoch-Jedrzejewska A Kardiol Pol; 2014; 72(2):122-5. PubMed ID: 24604503 [TBL] [Abstract][Full Text] [Related]
2. Vasopressin and its antagonists: what are their roles in acute medical care? Mitchell SL; Hunter JM Br J Anaesth; 2007 Aug; 99(2):154-8. PubMed ID: 17616565 [No Abstract] [Full Text] [Related]
3. Hemodynamic Evaluation of Vasomotion: Capacitance vs Conductance. Tyberg JV; Burrowes LM; Sheldon RS Can J Cardiol; 2016 Dec; 32(12):1378-1380. PubMed ID: 27687721 [No Abstract] [Full Text] [Related]
4. Neonatal blood pressure support: the use of inotropes, lusitropes, and other vasopressor agents. Noori S; Seri I Clin Perinatol; 2012 Mar; 39(1):221-38. PubMed ID: 22341548 [TBL] [Abstract][Full Text] [Related]
5. The apelinergic system: a promising therapeutic target. Falcão-Pires I; Ladeiras-Lopes R; Leite-Moreira AF Expert Opin Ther Targets; 2010 Jun; 14(6):633-45. PubMed ID: 20350050 [TBL] [Abstract][Full Text] [Related]
7. [Vasopressin as an alternative vasopressor in cardiopulmonary resuscitation. Study of the literature and comparison with adrenaline]. Wenzel V; Padosch SA; Lindner KH Dtsch Med Wochenschr; 1998 Jul; 123(28-29):877-82. PubMed ID: 9693659 [No Abstract] [Full Text] [Related]
8. Vassopressors and inotropes. Med Lett Drugs Ther; 2011 Nov; 53(1377):90-2. PubMed ID: 22075670 [No Abstract] [Full Text] [Related]
9. [Effect of nonsteroidal anti-inflammatory agents on the cardiovascular system]. Stepaniuk GI; Stoliarchuk AA Farmakol Toksikol; 1987; 50(5):89-93. PubMed ID: 3319688 [No Abstract] [Full Text] [Related]
10. Vasopressin in paediatric practice. Wolf A Paediatr Anaesth; 2008 Jul; 18(7):579-81. PubMed ID: 18616490 [No Abstract] [Full Text] [Related]
11. Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease. Overgaard CB; Dzavík V Circulation; 2008 Sep; 118(10):1047-56. PubMed ID: 18765387 [No Abstract] [Full Text] [Related]
12. Insights from systems pharmacology into cardiovascular drug discovery and therapy. Li P; Fu Y; Ru J; Huang C; Du J; Zheng C; Chen X; Li P; Lu A; Yang L; Wang Y BMC Syst Biol; 2014 Dec; 8():141. PubMed ID: 25539592 [TBL] [Abstract][Full Text] [Related]
14. The role of vasopressin in treating systemic inflammatory syndrome complicated by right ventricular failure. Vida VL; Mack R; Castañeda AR Cardiol Young; 2005 Feb; 15(1):88-90. PubMed ID: 15831170 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological approaches to the treatment of oxidative stress-induced cardiovascular dysfunctions. Zamora PL; Villamena FA Future Med Chem; 2013 Mar; 5(4):465-78. PubMed ID: 23495692 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of neuregulin-1 in cardiovascular disease. Mendes-Ferreira P; De Keulenaer GW; Leite-Moreira AF; Brás-Silva C Drug Discov Today; 2013 Sep; 18(17-18):836-42. PubMed ID: 23384772 [TBL] [Abstract][Full Text] [Related]
17. [Chronobiology and chronopharmacology of cardiovascular diseases]. Lemmer B Wien Med Wochenschr; 1995; 145(17-18):445-7. PubMed ID: 8588361 [TBL] [Abstract][Full Text] [Related]
18. RhoA/Rho-Kinase in the Cardiovascular System. Shimokawa H; Sunamura S; Satoh K Circ Res; 2016 Jan; 118(2):352-66. PubMed ID: 26838319 [TBL] [Abstract][Full Text] [Related]
19. Cardiovascular effects of sphingosine-1-phosphate (S1P). Levkau B Handb Exp Pharmacol; 2013; (216):147-70. PubMed ID: 23563656 [TBL] [Abstract][Full Text] [Related]
20. [The opiate system in the regulation of central hemodynamics]. Lishmanov IuB; Maslov LN Patol Fiziol Eksp Ter; 2003; (1):2-11. PubMed ID: 12652936 [No Abstract] [Full Text] [Related] [Next] [New Search]